Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous Lecanemab in Healthy Subjects
NCT05045716Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lecanemab in Alzheimer's disease (AD) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration, Area Under the Serum Concentration-time Curve From Time Zero to 72 Hours and 5 more. Started Sep 2021; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05045716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045716.